Bajrami, Ilirjana
The Francis Crick Institute
4 papers on CoChatORCID 0000-0003-2617-2938
Most cited papers
- Verified
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 373
- Verified
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation
PARP inhibition in cancer therapyinterferon and immune responses
Cited by 332
- Verified
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine
PARP inhibition in cancer therapySirtuins and Resveratrol in Medicine
Cited by 136
- Verified
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology
Protein Degradation and InhibitorsUbiquitin and proteasome pathways
Cited by 9
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free